Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Testing Drugs For Resistant TB Seen As Prelude To Trials In Wider Population

Executive Summary

A Phase II trial of Johnson & Johnson's investigational tuberculosis drug TMC207 is highlighted in a June 4 New England Journal of Medicine editorial by NIAID's Cliffton Barry, not only for its positive results, but for its contribution to encouraging trial designs that could facilitate TB drug development

You may also be interested in...



FDA Encourages TB Drug Development But Wary Of Promoting Resistance

FDA's approach to TB drug development demonstrates the traits Commissioner Margaret Hamburg wants in her agency - transparent, proactive, public health-oriented

FDA Encourages TB Drug Development But Wary Of Promoting Resistance

FDA's approach to TB drug development demonstrates the traits Commissioner Margaret Hamburg wants in her agency - transparent, proactive, public health-oriented

Tuberculosis Trial Design: FDA/Company Endpoint Talks Go Public At Cmte.

The approval pathway for drugs to treat multi-drug resistant tuberculosis became somewhat clearer for sponsors as FDA's Anti-Infective Drugs Advisory Committee weighed in on clinical trial endpoints at a June 3 meeting

Topics

UsernamePublicRestriction

Register

MT142464

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel